NEW YORK, Nov. 11 (GenomeWeb News) - Lynx Therapeutics said today that it has signed a multi-year, multi-million dollar services agreement with DuPont that extends a five-year agreement the companies initiated in 1998.

Under the extended arrangement, DuPont and its subsidiary, Pioneer Hi-Bred International, will continue using Lynx's Massively Parallel Signature Sequencing (MPSS) technology for the discovery and development of new agricultural traits and products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.